Cutler Group LP Akero Therapeutics, Inc. Put Options Transaction History

Cutler Group LP

11 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q1 2024 Apr 19, 2024	BUY	$17.76 - $31.18 $12,432 - $21,826	700 Added 700.0%	800 $2,000
Q4 2023 Jan 18, 2024	BUY	$11.38 - $50.33 $1,138 - $5,033	100 New	100 $0
Q2 2023 Jul 18, 2023	SELL	$36.89 - $56.88 $228,718 - $352,656	-6,200 Reduced 91.18%	600 $0
Q1 2023 May 01, 2023	SELL	$37.27 - $50.24 $883,299 - $1.19 Million	-23,700 Reduced 77.7%	6,800 $8,000
Q4 2022 Feb 07, 2023	SELL	$33.44 - $54.8 $110,351 - $180,840	-3,300 Reduced 9.76%	30,500 $13,000
Q3 2022 Oct 25, 2022	BUY	$10.15 - $34.05 $343,070 - $1.15 Million	33,800 New	33,800 $34,000
Q2 2021 Jul 19, 2021	SELL	$24.81 - $32.35 $42,177 - $54,995	-1,700 Closed	0 $0
Q1 2021 Apr 26, 2021	BUY	$24.04 - $34.19 $40,868 - $58,122	1,700 New	1,700 $4,000
Q4 2020 Jan 21, 2021	SELL	$25.12 - $29.89 $22,608 - $26,901	-900 Closed	0 $0
Q3 2020 Oct 27, 2020	BUY	$30.79 - $39.92 $24,632 - $31,936	800 Added 800.0%	900 $9,000
Q2 2020 Jul 22, 2020	BUY	$19.25 - $26.76 $1,925 - $2,676	100 New	100 $0

270

86M

1.02M

823K

Ticker AKRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,417,600
Market Cap $2.51B
Description
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.